Literature DB >> 35222119

Childhood Trauma in Patients With PAH-Prevalence, Impact on QoL, and Mental Health-A Preliminary Report.

Da-Hee Park1,2, Tanja Meltendorf3, Kai G Kahl3, Jan C Kamp1,2, Manuel J Richter4,5, Henning Gall4,5, Hossein A Ghofrani4,5, Marius M Hoeper1,2, Karen M Olsson1,2, Jan Fuge1,2.   

Abstract

BACKGROUND/
OBJECTIVE: Child maltreatment is associated with increased risk of psychological consequences, contributes to morbidity and has long lasting effects on mental health and quality of life. Child maltreatment has not been assessed in patients with pulmonary arterial hypertension (PAH). We examined the prevalence of child maltreatment and determined their impact on disease severity in patients with PAH.
METHODS: A cross-sectional observational multicenter study at two PH centers in Germany was conducted. Patients with a confirmed diagnosis of PAH were given a self-administered questionnaire. Child maltreatment using the Childhood Trauma Questionnaire (CTQ), quality of life (QoL), anxiety, depression, and lifestyle factors were assessed and enhanced by clinical parameters 6-min walk distance (6MWD), WHO functional class (WHO FC), and serum levels of N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP). Prevalence rates of child maltreatment were compared to the general population and impact of child maltreatment on disease severity was calculated by logistic regression analysis.
RESULTS: Two-hundred and seventeen patients, 71% female and a median age of 56 years were enrolled in this study. Patients with PAH had higher rates of emotional abuse and lower rates of physical neglect compared to the German population while rates of emotional neglect, physical abuse, and sexual abuse did not differ between patients and German population. Patients with any form of child maltreatment were more likely to be active smokers, had a worse QoL and more anxiety or depression. Moderate associations between child maltreatment, mental health, QoL, lifestyle factors and clinical parameters could be observed. Logistic regression analysis showed a significant impact of CTQ-total score on disease severity with an OR of 1.022 (95%-CI: 1.001-1.042, p = 0.035).
CONCLUSION: We found a higher rate of child maltreatment in patients with PAH in comparison to the German population. Correlations suggest moderate associations between CTQ-scores and mental health as well as QoL. Child maltreatment had significant impact on disease severity. However, effects were moderate. We conclude that child maltreatment has effects on mental health and quality of life in patients with PAH and may have limited effect on disease severity.
Copyright © 2022 Park, Meltendorf, Kahl, Kamp, Richter, Gall, Ghofrani, Hoeper, Olsson and Fuge.

Entities:  

Keywords:  child maltreatment; mental health; prevalence; pulmonary arterial hypertension; pulmonary hypertension; quality of life

Year:  2022        PMID: 35222119      PMCID: PMC8866231          DOI: 10.3389/fpsyt.2022.812862

Source DB:  PubMed          Journal:  Front Psychiatry        ISSN: 1664-0640            Impact factor:   4.157


Introduction

Pulmonary arterial hypertension (PAH) is progressive pulmonary vascular disease. Characterized by remodeling of pulmonary vasculature it leads to increased pulmonary vascular resistance (1, 2). Patients with PAH are experiencing symptoms such as dyspnea on exertion, fatigue and with disease progression potentially clinical signs of heart failure. These debilitating symptoms impair physical activities and quality of life (QoL) (3, 4). While the disease remains fatal as none of the currently available drugs are curative, improvement of therapeutic options, clinical outcomes and life expectancy have put questions of patient's quality of life, mental health, emotional, and social burden are on the forefront of current research (5–8). Data on prevalence of psychiatric disorders in PAH patients (9, 10) is still scarce. Olsson et al. demonstrated a higher prevalence of anxiety and depression disorders with negative impact on QoL in PAH compared to levels in the German population (11, 12). Child maltreatment may pose an additional risk factor associated with lower QoL and mental disorders in patients with PAH. Several studies have identified child maltreatment as an important contributing factor to the incidence and severity of depressive disorders (13). Child maltreatment is defined as the abuse and neglect against a child under the age of 18 by a parent or other caregivers. It includes all types of physical and/or emotional ill-treatment, sexual abuse and neglect which results in actual or potential harm to the child's health, survival, development, or dignity in the context of a relationship of responsibility, trust, or power (14). It has been associated with poorer overall health, greater physical, and emotional functional disability and higher degree of health risk behavior. Patients with multiple types of maltreatment showed greatest worsening of self-reported health symptoms (15). Child maltreatment is associated with various diseases such as the development of cardiovascular diseases, type 2 diabetes or chronic obstructive pulmonary diseases leading to higher mortality (16–18). Proskynitopoulos et al. (19) found increased prevalence of child maltreatment in adults with congenital heart disease compared to the general German population. Higher total Child trauma questionnaire (CTQ) scores correlated with decreased quality of life, higher rates of anxiety, and depression and contributed to the prediction of New York Heart Association (NYHA) scores (19). The present study aimed to assess the (i) prevalence of child maltreatment in patients with PAH and (ii) to compare this with the prevalence in the German general public as well as (iii) to assess the impact, differences and associations of child maltreatment on disease severity, lifestyle factors, mental health, and QoL in patients with PAH.

Methods

This cross-sectional observational multicentre study included patients with a confirmed diagnosis of PAH at two participating PH referral centers (Hannover Medical School and University of Giessen and Marburg, both in Germany). The study concept was developed in cooperation with patient organizations as suggested during the latest Pulmonary Hypertension World Symposium in 2018 (20). All patients gave written informed consent. The study was approved by local institutional review boards (Nr. 8540_BO_K_2019 for Hannover and Nr. 21119 for Giessen and Marburg). Patients were contacted between September 2019 and March 2020. This study was conducted by a self-administrated questionnaire.

Patient Setting and Clinical Parameters

Patients were selected based on diagnosis of PAH according to current criteria (1) and age ≥ 18 years. Assessment included hemodynamics from right heart catherization at time of diagnosis, 6-minute walk distance (6MWD), WHO functional class (FC), and serum levels of N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP). Risk assessment for our cohort was based on three variables FC, 6MWD, and BNP/NT-proBNP as previously described (21, 22). Each variable was graded with a number as low risk (1), intermediate risk (2), and high risk (3). The average risk was calculated by dividing the sum of the grades by the number of available variables and rounding to the next integer (23).

Assessment of Child Maltreatment

Child maltreatment was assessed using the German version of the Childhood Trauma Questionnaire CTQ (24). The CTQ consists of a 28-item self-rating scale divided in five subscales inquiring five areas: emotional abuse, physical abuse, sexual abuse, emotional neglect, and physical neglect. The items are rated from 1 (never true) to 5 (very often true). The subscale scores range from 5 to 25 with an overall score from 25 to 125 points. Several studies have supported the reliability and validity of reported childhood trauma obtained with this instrument, discriminant validity with structured trauma interviews and corroboration with independent data (24). Thresholds presented by Walker et al. (15) were used to construct groups with either form of maltreatment or no maltreatment. Child maltreatment was classified when threshold scores for emotional abuse (10), emotional neglect (15), physical abuse (8), physical neglect (8), and sexual abuse (8) were met. The CTQ-derived prevalence rates and mean-values of child maltreatment were compared to the German general population described by Iffland et al. (25).

Assessment of Symptoms of Anxiety and Depression and Quality of Life

Symptoms of anxiety and depression were assessed with participants completing the Hospital Anxiety and Depression Scale (HADS) (26). The HADS questionnaire is divided into subscales for anxiety (HADS-A) and depression (HADS-D), each containing seven questions for a maximum of 21 points per subscale. The higher score indicating a more severe anxiety or depression. Zigmond et al. (26) proposed a score >11 per subscale to be associated with significant anxiety or depression. A cut-off score of 8 or above for both HADS-A and HADS-D was validated, showing probable signs of anxiety or depression (27, 28). The World Health Organization Quality of Life [WHO-QoL-BREF (29)] was used to assess quality of life.

Statistical Analysis

IBM SPSS Statistics (version 28.0, IBM Corp., Armonk, New York) and Stata 13.0 (State Corp LP, College Station, Texas, USA) statistical software programs were used for statistical analysis. Continuous parameters are presented as median and interquartile range (Q25-Q75) or as mean and standard deviation (SD). Categorical variables are presented as number (n) and percent (%). Comparisons of continuous parameters were conducted using t-test or Mann-Whitney U-test (if not normally distributed or ordinal scaled) and comparison of categorical parameters by using Chi-square-test or fisher's exact test, unless indicated otherwise. Correlations of continuous and ordinal parameters were assessed using Pearson correlation coefficient. Parameters were CTQ-scores, lifestyle factors (exercise, drinks per week, and smoking intensity) and clinical parameters such as BMI, HADS-scores, QoL, 6MWD, and WHO FC. Logistic regression analysis was conducted to assess impact of CTQ-score on clinical outcome parameter WHO FC as surrogate for disease severity (WHO FC I and II vs. WHO FC III and IV was used as binary outcome). Further univariate logistic regression was conducted to assess impact of child maltreatment (any positive CTQ-subscore) on anxiety or depression disorder. Nagelkerke's R2 was determined to assess model quality. All tests were two-sided, p < 0.05 were considered statistically significant. P-values of multiple correlations were adjusted using the Benjamini–Hochberg-procedure.

Results

This patient cohort was previously described in the PEPPAH-study (12). A total of 327 patients were approached in this study. Two hundred and seventeen patients (66%) agreed to participate and returned the questionnaires (Figure 1). Patient characteristics are shown in Table 1. The majority of patients were female (n = 155, 71%); median age was 56 (49-67) years. All patients were treated with PAH medications, most of them (47%) with dual combination therapy. Nearly all patients (96%) fell in the low or intermediate ERS risk score category. Patients with any form of child maltreatment were more likely to be active smokers, had a worse overall QoL and more anxiety and depression. Trends could be observed in 6MWD with more than 30 m difference in patients with or without any form of child maltreatment (Table 1). Disease severity indicated by ERS risk status, WHO FC and NTproBNP, hemodynamics at time of diagnosis, and PAH treatment did not differ between groups.
Figure 1

Flowchart of patient inclusion.

Table 1

Patient characteristics.

All patients n = 217 Patients with any CTQ positive subscore n = 108 (50%) Patients without any CTQ positive subscore n = 109 (50%) p-value of group comparison
Age—years56 (49-67)55 (41-65)57 (45-66)0.422
Sex—female (%)155 (71%)74 (69%)81 (74%)0.345
BMI (kg/m2)26 (23-31)26 (23-31)26 (23-31)0.813
Time since PAH diagnosis (years)6 (3-11)6 (2-11)7 (4-13)0.062
Diagnosis—n (%)
   -1.1 IPAH122 (56%)66 (61%)56 (51%)0.233c
   -1.2 HPAH25 (12%)13 (12%)12 (11%)
   -1.4 Associated PAH70 (32%)29 (27%)41 (38%)
WHO FC
   -I, n (%)20 (9%)7 (7%)13 (12%)0.439c
   -II, n (%)92 (43%)45 (42%)47 (44%)
   -III, n (%)93 (43%)51 (47%)42 (39%)
   -IV, n (%)10 (5%)5 (5%)5 (5%)
ESC/ERS risk status—n (%)
   -Low107 (50%)52 (49%)55 (52%)0.799c
   -Intermediate97 (46%)51 (53%)46 (47%)
   -High9 (4%)4 (44%)5 (56%)
6MWD439 (353–521)423 (339–502)454 (371–539)0.061
NT-proBNP (ng/l), n = 192184 (88–517)169 (74–419)207 (104–586)0.961
DLCO (% pred.), n = 13862 (47-74)64 (42-73)61 (48-74)0.844
paO2, mmHg67 (60–75)67 (60–76)67 (61–75)0.788
Hemodynamics at diagnosis
   -mPAP (mmHg)48 (41-57)48 (41-58)49 (41-58)0.651
   -PAWP (mmHg)9 (6-12)9 (6-12)9 (6-12)0.794
   -CI (l/min/m2)2.4 (2.0–2.9)2.4 (2.0–3.0)2.4 (2.0–2.7)0.284
   -PVR (dyn·s·cm−5)707 (501–947)689 (505–951)752 (498–927)0.914
PH-therapy—n (%)
   -Monotherapy44 (20%)21 (19%)23 (21%)0.673c
   -Double combination therapy102 (47%)54 (50%)48 (44%)
   -Triple combination therapy71 (33%)33 (31%)38 (35%)
Smoking status
   -Active, n (%)24 (11%)17 (16%)7 (6%)0.021c
   -Former, n (%)31 (14%)19 (18%)12 (11%)
   -Never, n (%)162 (75%)72 (67%)90 (83%)
   -Packyears14 (5-25)15 (6-23)9 (4-33)0.495
Alcohol drinking (drinks per week)0.8 ± 2.00.9 ± 2.50.8 ± 1.10.772a
Exercise score (points)3 (2-4)3 (2-3)3 (2-4)0.906b
HADS-A (points)6 (2-9)7 (3-10)5 (2-9) 0.034
HADS-D (points)5 (2-8)6 (3-9)4 (2-7) 0.002
QoL-overall (points)50 (38-75)50 (38-63)63 (44-75) 0.026
QoL-psych (points)71 (58–79)63 (50-79)71 (63–83) 0.020
QoL-physical (points)57 (45-75)57 (43-71)64 (50-75) <0.001
QoL-social (points)67 (58-83)67 (58-83)67 (50-75) 0.009
QoL-environment (points)78 (69–88)75 (63–84)78 (70–88) 0.012

Continuous variables are stated as median and interquartile ranges (IQR) and categorical variables are stated as n and percent (%), unless indicated otherwise. All p-values were derived using t-test, unless indicated otherwise.

Mean and SD because of distribution of the data.

Non-parametric Mann–Whitney U-test because of ordinal scale of the variable.

Chi.

BMI, body mass index; QoL, quality of life; HADS-A, Hospital Anxiety and Depression Scale—anxiety; HADS-D, Hospital Anxiety and Depression Scale—Depression; I/HPAH, idiopathic or heritable pulmonary arterial hypertension; WHO FC, World Health Organization Functional Class; 6MWD, 6-min walking distance; NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide; DLCO, diffusion capacity of the lung for carbon monoxide; paO.

Flowchart of patient inclusion. Patient characteristics. Continuous variables are stated as median and interquartile ranges (IQR) and categorical variables are stated as n and percent (%), unless indicated otherwise. All p-values were derived using t-test, unless indicated otherwise. Mean and SD because of distribution of the data. Non-parametric Mann–Whitney U-test because of ordinal scale of the variable. Chi. BMI, body mass index; QoL, quality of life; HADS-A, Hospital Anxiety and Depression Scale—anxiety; HADS-D, Hospital Anxiety and Depression Scale—Depression; I/HPAH, idiopathic or heritable pulmonary arterial hypertension; WHO FC, World Health Organization Functional Class; 6MWD, 6-min walking distance; NT-proBNP, N-terminal fragment of pro-brain natriuretic peptide; DLCO, diffusion capacity of the lung for carbon monoxide; paO.

Prevalence of Child Maltreatment in Patients With PAH

In this study, child maltreatment with a least one subgroup above threshold was detected in fifty percent of the patients (Table 1). Emotional abuse and emotional neglect were about 2 times more frequent in patients with PAH than in the general population (Table 1; Figure 2). Patients with PAH had a significantly higher total CTQ score (p < 0.001), while physical neglect was more prevalent in the general German population (48.4 vs. 36.4%, p = 0.041) and physical abuse did not significantly differ between both groups (14.3 vs. 12.0%, p = 0.458). Sexual abuse was reported under 10% in both patients with PAH and the general population (Table 2).
Figure 2

Subscores of childhood trauma questionnaire of patients with pulmonary arterial hypertension.

Table 2

Scores and prevalence of child maltreatment in patients with PAH compared to German population.

Item PAH German population (25) p
n = 217 n = 2,500
Comparison of CTQ-scores, Mean (SD)
   -CTQ-total score41.84 ± 14.4335.99 ± 10.48 <0.001
   -CTQ-emotional abuse7.68 ± 4.006.51 ± 2.60 <0.001
   -CTQ-emotional neglect9.58 ± 4.8810.09 ± 4.230.093
   -CTQ-physical abuse6.19 ± 2.835.88 ± 2.17 0.049
   -CTQ-physical neglect7.18 ± 2.758.15 ± 3.02 <0.001
   -CTQ-sexual abuse5.54 ± 2.245.45 ± 1.660.458
Comparison of CTQ-categories, n (%)
   -CTQ-emotional abuse43 (19.8%)254 (10.2%) <0.001
   -CTQ-emotional neglect42 (19.4%)348 (13.9%)0.078
   -CTQ-physical abuse31 (14.3%)301 (12.0%)0.458
   -CTQ-physical neglect79 (36.4%)1,210 (48.4%) 0.041
   -CTQ-sexual abuse14 (6.5%)156 (6.2%)0.920

Continuous variables are stated as mean and standard deviation and categorical variables are stated as n and percent (%).

CTQ, childhood trauma questionnaire; PAH, pulmonary arterial hypertension; SD, standard deviation; Statistically significant values as bold.

Subscores of childhood trauma questionnaire of patients with pulmonary arterial hypertension. Scores and prevalence of child maltreatment in patients with PAH compared to German population. Continuous variables are stated as mean and standard deviation and categorical variables are stated as n and percent (%). CTQ, childhood trauma questionnaire; PAH, pulmonary arterial hypertension; SD, standard deviation; Statistically significant values as bold.

Correlation of CTQ Subscores on Quality of Life, Mental Health, Lifestyle, and Clinical Parameters

Moderate associations between CTQ-scores, mental health, QoL, lifestyle factors, and clinical parameters could be observed (see Table 3). Higher CTQ emotional-, physical, or total scores were correlated with higher HADS depression and anxiety scores (r = 0.201–0.401, p < 0.001) while being negatively correlated with QoL (r = −0.200 to −0.315, p < 0.001). History of smoking and WHO FC were positively correlated with emotional and physical CTQ-scores (r = 0.113–0.216). Total CTQ-scores were negatively correlated to 6MWD (r = −0.145 to r = −0.204, p < 0.005) whereas exercise and drinks per week were not significantly related. There were no significant association between CTQ-sexual abuse and any evaluatedparameter.
Table 3

Correlations of CTQ-scores in PAH with HADS, QoL, Lifestyle and 6MWD, and WHO FC.

HADS-D HADS-A QoL BMI Exercise Drinks Smoking WHO FC 6MWD
CTQ-total score0.368**0.351**−0.315**0.158*−0.068−0.0710.188*0.186*−0.192*
CTQ-emotional abuse0.388**0.401**−0.302**0.126−0.039−0.0270.181**0.125−0.174*
CTQ-emotional neglect0.316**0.255**−0.308**0.121−0.056−0.0820.1130.210*−0.145*
CTQ-physical abuse0.262**0.268**−0.200*0.139*−0.081−0.0660.157*0.118*−0.146*
CTQ-physical neglect0.251**0.204*−0.269*0.131−0.041−0.0880.216*0.192*−0.204*
CTQ-sexual abuse0.1120.106−0.0560.123−0.0330.0010.0210.049−0.097

Pearson correlation coefficient. Statistically significant values are marked using asterisk,

p < 0.001;

p < 0.05.

BMI, body mass index; CTQ, childhood trauma questionnaire; QoL, quality of life; HADS-A, Hospital Anxiety and Depression Scale—anxiety; HADS-D, Hospital Anxiety and Depression Scale—Depression; PAH, pulmonary arterial hypertension; WHO FC, World Health Organization Functional Class; 6MWD, 6-min walking distance.

Correlations of CTQ-scores in PAH with HADS, QoL, Lifestyle and 6MWD, and WHO FC. Pearson correlation coefficient. Statistically significant values are marked using asterisk, p < 0.001; p < 0.05. BMI, body mass index; CTQ, childhood trauma questionnaire; QoL, quality of life; HADS-A, Hospital Anxiety and Depression Scale—anxiety; HADS-D, Hospital Anxiety and Depression Scale—Depression; PAH, pulmonary arterial hypertension; WHO FC, World Health Organization Functional Class; 6MWD, 6-min walking distance.

Impact of CTQ on Disease Severity and Mental Health

Univariate logistic regression analysis on disease severity (WHO FC I+II vs. WHO FC III+IV) revealed a significant impact of CTQ-total score with an OR of 1.022 (95%-CI: 1.001–1.042, p = 0.035) while the model describes 2.9% of the independent variable. Further univariate regression analysis showed that patients with reported emotional neglect had a 6.8% higher chance (95%-CI: 1.009–1.131, p = 0.023) of being in WHO FC III or IV per CTQ point increase. Model accuracy was 3.3%. Impact of any positive CTQ-subscore on anxiety had an OR of 1.678 (95%-CI: 0.788–3.574, p = 0.179) while impact on depression showed an OR of 2.761 (95%-CI: 1.369–5.209, p = 0.004) while model accuracy was 1.5 and 6%, respectively.

Discussion

To the best of our knowledge this is the first study to assess the prevalence of child maltreatment in patients with PAH. Patients with PAH had a higher overall CTQ-score with fifty percent of our patients exceeding the threshold for any subscore of child maltreatment. In these patients, moderate associations between CTQ-scores and QoL, anxiety and depression, WHO FC, and 6MWD could be detected. Higher prevalence of CTQ-scores were mainly driven by higher subscores in emotional abuse or physical abuse. This is in line with previous observations from patients with congenital heart disease (19). While absolute scores were higher in patients with PAH, both groups reported only moderately elevated scores on the scale of 5–25 points per subscore (as seen in Figure 2). Inversely physical neglect was comparatively more frequent in the general population than in patients with PAH. It has been discussed that elderly who experienced privation of (post-)war year were more likely to report physical neglect (25). With comparatively weak psychometric properties and weak internal consistency, comparisons for the physical neglect subscale discussion on impact can only be held cautiously. Several severe long-term consequences of child maltreatment have been studied and suggested. Ranging from mentioned physical health, psychological to behavioral, and societal consequences. Most children who experienced child maltreatment are often affected by many other adversities such as domestic violence, poverty, and parental substance abuse (30). Child maltreatment poses a higher risk on the development of mental disorders such as depression (31–34). Olsson et al. have recently demonstrated a higher prevalence of mental disorders in patients with PAH. Our findings indicate a correlation between higher CTQ scores and higher HADS depression and anxiety scores. Gamble et al. (35) in as early as 2006 had described the correlation between childhood trauma and severity of anxiety and depression. Similarly, we demonstrated impact of child maltreatment on the diagnosis of depression, which is in line with these previous studies. Several studies examining impact of child maltreatment on disease outcomes saw attenuation of the relationship between child maltreatment and disease when adjusting for mental disorder (36). Our data supports existing evidence in indicating that child maltreatment is a risk factor for mental disorders which themselves may be mediators for disease severity of PAH (36). QoL contributes to the evaluation of emerging PAH treatments as well as disease course. QoL in patients with PAH is severely impaired by clinical symptoms as well as emotional domains (20, 37). Mathai et al. (38) have found QoL to be a predictor of outcomes in PAH and thus a target for therapeutic interventions. Child maltreatment in patients with PAH correlate with worse QoL. This is in line previous studies such as Corso et al. who demonstrated significant and sustained losses of QoL in adulthood of persons who experienced child maltreatment (39, 40). Several studies have demonstrated association between child maltreatment and cardiometabolic diseases such as systemic hypertension, ischemic heart disease, and chronic heart disease (41, 42). Many authors examined child maltreatment as a composite measure of adversity and reported a dose-response relationship between number of childhood adversities and heightened risk for cardiometabolic diseases. Overall, CTQ scores were associated with disease severity measured by WHO FC. In a subscore analysis of our study, we found that patients with higher scores in emotional neglect had a significantly higher chance of being in a higher WHO FC per CTQ point increase. While this impact might suggest negative influence on disease course, morbidity, and mortality model accuracy is comparatively low. Clinical signs of right heart failure, 6MWD, NT-proBNP/BNP, and WHO FC are strong indicators of disease severity and risk status in patients with PAH (23). Arguably these somatic factors play a more prominent role on disease severity with a minor role of child maltreatment and by association mental disorders.

Limitations

Our paper has strength and limitations. Data for childhood maltreatment, mental health and QoL were derived using a self-administered, paper-based questionnaire. Reliable measurements of prevalence and severity of child maltreatment have yet relied on self-reports, showing discrepancies of rates compared to reports of child-protection agencies (43, 44). Median global prevalence rates differ substantially by maltreatment type, gender and by continent with varying number of studies and available data (45). Only two German PH-centers were involved in this study which might cause selection bias. This study was carried out between September 2019 and March 2020. In January, the Corona virus pandemic hit Germany and this study didn't control for any possible impact on mental disease during this time. Of note, Park et al. (46) have studied effects on first waves of corona virus pandemic on a subsample of this cohort and found minor changes in mental health due to the corona virus pandemic. However, a strength is relatively large sample size of PAH patients given that PAH is a rare disease as both participating centers are large university-based tertiary-level referral centers.

Conclusion

In the present study, child maltreatment, in particular, subscores for emotional abuse and physical abuse was more prevalent in patients with PAH than in the general population. The presence of child maltreatment was associated with a higher likelihood of anxiety and depression and reduction in QoL. Child maltreatment in patients with PAH might play a role in disease severity. With wide ranges of long-term consequences of child maltreatment, screening for a history of child maltreatment can help physicians in assessment of patients' needs and treatment options. This should be taken into consideration in addition to more widely acknowledged impact of mental disorders and QoL on PAH. Psychosocial interventions as a treatment approach have been proven effective in patients with a history of child maltreatment (47–49). Integrating past experiences and psychological problems in the care and treatment of patients with PAH is recommended. The lasting consequences of child maltreatment warrant further investigation.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics Statement

The studies involving human participants were reviewed and approved by Hannover Medical School and University of Giessen and Marburg. The patients/participants provided their written informed consent to participate in this study.

Author Contributions

DHP was responsible for study design, implementation of the study, data collection, data interpretation, and drafting the manuscript. TM was responsible for data collection and revising the manuscript. KK was responsible for study design, data interpretation, and revising the manuscript. JK was responsible for data interpretation and revising the manuscript. MR, HG, and HAG were responsible for implementation of the study and critically revising the manuscript. MH was responsible for implementation of the study, data interpretation, and critically revising the manuscript. KO was responsible for study design, implementation of the study, data interpretation, and critically revising the manuscript. JF was responsible for study design, implementation of the study, data collection, statistical analysis, data interpretation, and drafting the manuscript. All authors contributed to the article and approved the submitted version.

Conflict of Interest

DHP has received honoraria for lectures and/or consultations from Janssen. KK has received honoraria for consultations and/or lectures from Eli Lilly, Janssen, Lundbeck, Neuraxpharm, Otsuka, Pfizer, Servier, Schwabe, Takeda, and Trommsdorff/Ferrer, Alexion, and CannaXan (advisory board). HG has received personal fees from Actelion, personal fees from AstraZeneca, personal fees from Bayer, personal fees from BMS, personal fees from GSK, personal fees from Janssen-Cilag, personal fees from Lilly, personal fees from MSD, personal fees from Novartis, personal fees from OMT, personal fees from Pfizer, personal fees from United Therapeutics, outside the submitted work. HG has received fees from Actelion, Bayer, Gilead, GSK, MSD, Pfizer, and United Therapeutics, outside the present work. HAG has received honoraria for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD and Pfizer, all outside the present study. KO has received honoraria for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD, United Therapeutics and Pfizer, all outside the present study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
  46 in total

1.  Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.

Authors:  Marius M Hoeper; Tilmann Kramer; Zixuan Pan; Christina A Eichstaedt; Jens Spiesshoefer; Nicola Benjamin; Karen M Olsson; Katrin Meyer; Carmine Dario Vizza; Anton Vonk-Noordegraaf; Oliver Distler; Christian Opitz; J Simon R Gibbs; Marion Delcroix; H Ardeschir Ghofrani; Doerte Huscher; David Pittrow; Stephan Rosenkranz; Ekkehard Grünig
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group.

Authors: 
Journal:  Psychol Med       Date:  1998-05       Impact factor: 7.723

3.  The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension.

Authors:  Raymond L Benza; Mardi Gomberg-Maitland; Dave P Miller; Adaani Frost; Robert P Frantz; Aimee J Foreman; David B Badesch; Michael D McGoon
Journal:  Chest       Date:  2011-06-16       Impact factor: 9.410

4.  Quality of life and psychological symptoms in patients with pulmonary hypertension.

Authors:  Tania T Von Visger; Kristin K Kuntz; Gary S Phillips; Vedat O Yildiz; Namita Sood
Journal:  Heart Lung       Date:  2018-02-01       Impact factor: 2.210

5.  Health-related quality of life in patients with pulmonary arterial hypertension.

Authors:  Shirin Shafazand; Mary K Goldstein; Ramona L Doyle; Mark A Hlatky; Michael K Gould
Journal:  Chest       Date:  2004-11       Impact factor: 9.410

6.  Child abuse and neglect and the development of mental disorders in the general population.

Authors:  P Cohen; J Brown; E Smaile
Journal:  Dev Psychopathol       Date:  2001

7.  Childhood Maltreatment and Health Impact: The Examples of Cardiovascular Disease and Type 2 Diabetes Mellitus in Adults.

Authors:  Archana Basu; Katie A McLaughlin; Supriya Misra; Karestan C Koenen
Journal:  Clin Psychol (New York)       Date:  2017-04-10

8.  Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians' diagnoses.

Authors:  Bernd Löwe; Robert L Spitzer; Kerstin Gräfe; Kurt Kroenke; Andrea Quenter; Stephan Zipfel; Christine Buchholz; Steffen Witte; Wolfgang Herzog
Journal:  J Affect Disord       Date:  2004-02       Impact factor: 4.839

9.  The impact and financial burden of pulmonary arterial hypertension on patients and caregivers: results from a national survey.

Authors:  Zhenguo Zhai; Xia Zhou; Shuai Zhang; Wanmu Xie; Jun Wan; Tuguang Kuang; Yuanhua Yang; Huan Huang; Chen Wang
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

10.  Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial Hypertension.

Authors:  Karen M Olsson; Tanja Meltendorf; Jan Fuge; Jan C Kamp; Da-Hee Park; Manuel J Richter; Henning Gall; Hossein A Ghofrani; Pisana Ferrari; Ralf Schmiedel; Hans-Dieter Kulla; Ivo Heitland; Nicole Lepsy; Madelaine-Rachel Dering; Marius M Hoeper; Kai G Kahl
Journal:  Front Psychiatry       Date:  2021-05-31       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.